GenSpera commences treatment in G-202 Phase I trial for solid tumors

GenSpera, Inc. (OTC.BB: GNSZ) announced that the first patient was treated in the Phase I clinical study of its cancer chemotherapeutic agent, G-202, at the University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. The trial is also being conducted at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

“We are delighted to have reached this important milestone in the development of G-202”

“We are delighted to have reached this important milestone in the development of G-202,” commented Craig Dionne, Ph.D., Genspera CEO and President. “G-202 is truly a new type of cancer chemotherapeutic agent with the potential to have significant impact on patients with many types of solid tumors.”

The G-202 Phase I study is designed to enroll up to thirty patients with cancers that have progressed after treatment with other anti-cancer agents. The primary endpoints of the open-label, dose-escalation study are to determine the safety, tolerability and pharmacokinetics of the drug, although the design allows the collection of efficacy data as well.

SOURCE GenSpera, Inc.